General Principles and Guidelines

  • John AnthonyEmail author
Part of the Current Cardiovascular Therapy book series (CCT)


Drugs are commonly taken during pregnancy, both by prescription and as over the counter medication. Drugs used during pregnancy may show an altered pharmacodynamic profile when compared to their use in the non-pregnant population. In addition, they may cross the placenta and result in adverse effects on the fetus. There are relatively few data outlining the pharmacodynamic changes characteristic of pregnancy and new drugs are seldom tested in pregnancy when clinical trials are instituted. Prescribing drugs in pregnancy necessarily requires some knowledge of how the pregnancy may alter the pharmacodynamic profile of individual agents and a consideration of any potential adverse effects on the fetus. The use of prescription drugs can only be justified when the anticipated benefits outweigh any known risk. Prescription drugs will be needed in the management of cardiac disease and an understanding of pregnancy physiology will assist in assessing the likely efficacy and risks of these drugs.


Cardiac Output Antiarrhythmic Drug Effective Renal Plasma Flow Peripartum Cardiomyopathy Direct Renin Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Anderson GD. Pregnancy-induced changes in pharmacokinetics. Clin Pharmacokinet. 2005;44(10):989–1008.PubMedCrossRefGoogle Scholar
  2. Assali NS, Rauramo L, Peltonen T. Uterine and fetal blood flow and oxygen consumption in early human pregnancy. Am J Obstet Gynecol. 1960;79:86.PubMedGoogle Scholar
  3. Caton AR, Bell EM, Druschel CM, et al. Antihypertensive medication use during pregnancy and the risk of cardiovascular malformations. Hypertension. 2009;54:63–70.PubMedCrossRefGoogle Scholar
  4. Davison JM, Noble MC. Serial changes in 24-hour creatinine clearance during normal menstrual cycles and the first trimester of pregnancy. Br J Obstet Gynaecol. 1981;88:10.PubMedCrossRefGoogle Scholar
  5. de Swiet M. The cardiovascular system. In: Hytten F, Chamberlain G, editors. Clinical physiology in obstetrics. Oxford: Blackwell Scientific Publications; 1980.Google Scholar
  6. Feghali MN, Mattison DR. Clinical therapeutics in pregnancy. J Biomed Biotechnol. 2011:783528. doi: 10.1155/2011/783528. Published online 2011 July 6.
  7. Isoherranen N, Thummel KE. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab Dispos. 2013;41:256–62.PubMedCrossRefGoogle Scholar
  8. Kenny LC, Baker PN, Kendall DA, Randall MD, Dunn WR. Mechanisms of endothelium-dependent vasodilator responses in human myometrial small arteries in normal pregnancy and pre-eclampsia. Clin Sci (Lond). 2002;103(1):67–73.CrossRefGoogle Scholar
  9. Koren G, Pastuszak A, Ito S. Drugs in pregnancy. N Engl J Med. 1998;338(16):1128–37.PubMedCrossRefGoogle Scholar
  10. Mabie WC, DiSessa TG, Crocker LG, et al. A longitudinal study of cardiac output in normal human pregnancy. Am J Obstet Gynecol. 1994;170:849.PubMedCrossRefGoogle Scholar
  11. Rakusan K. Drugs in pregnancy: implications for a cardiologist. Exp Clin Cardiol. 2010;15(4):e100–e103.PubMedGoogle Scholar
  12. Sibai BM, Frangieh A. Maternal adaptation to pregnancy. Curr Opin Obstet Gynecol. 1995;7:420.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag London 2014

Authors and Affiliations

  1. 1.Department of Obstetrics and GynaecologyGroote Schuur HospitalCape TownSouth Africa

Personalised recommendations